3-ft has been researched along with Cancer of Stomach in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (66.67) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Anai, H; Emi, Y; Kohnoe, S; Maehara, Y; Sakaguchi, Y; Sugimachi, K | 1 |
| Arima, S; Futami, K; Shimura, H; Toriya, H | 1 |
| Kakehi, M; Mizuguchi, N; Mukojima, T; Watai, K | 1 |
3 other study(ies) available for 3-ft and Cancer of Stomach
| Article | Year |
|---|---|
A protein-bound polysaccharide immunomodulator, PSK, does not suppress the conversion from 1-(2-tetrahydrofuryl)-5-fluorouracil to 5-fluorouracil in patients with gastric cancer.
Topics: Antibiotics, Antineoplastic; Biotransformation; Depression, Chemical; Female; Fluorouracil; Humans; Injections, Intravenous; Male; Middle Aged; Proteoglycans; Stomach Neoplasms; Tegafur | 1991 |
The uptake of anticancer drugs by tumor tissues and lymph node and the effectiveness of postoperative adjuvant chemotherapy on survival time.
Topics: Combined Modality Therapy; Fluorouracil; Humans; Lymph Nodes; Prognosis; Stomach Neoplasms; Tegafur; Time Factors | 1989 |
[Thermochemotherapy of cancer of the stomach].
Topics: Antineoplastic Agents; Humans; Hyperthermia, Induced; Mitomycin; Mitomycins; Stomach Neoplasms; Tegafur | 1988 |